News

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Feb 18, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference

Non-regulatory Press Release
Read more
Feb 13, 2026
2026
Press Release Regulatory

Elicera Therapeutics AB (publ) Year-End 1 January – 31 December 2025

Regulatory Press Release
Read more
Feb 11, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study

Non-regulatory Press Release
Read more
Jan 22, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics’ CSO invited to present at multiple scientific conferences

Non-regulatory Press Release
Read more
Jan 9, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors

Non-regulatory Press Release
Read more
Dec 23, 2025
2025
Press Release Regulatory

Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Regulatory Press Release
Read more
Nov 14, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 30 September 2025

Regulatory Press Release
Read more
Nov 13, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research

Non-regulatory Press Release
Read more
Oct 23, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Regulatory Press Release
Read more
Sep 28, 2025
2025
News

Gunilla Enblad, advisor to Elicera Therapeutics, and Mats Hellström appear in UNT and Expressen to talk about the CARMA-trial.

News
Read more
Sep 19, 2025
2025
Press Release Non-regulatory

Elicera clarifies status of the iTANK-platform patent application in the U.S.

Non-regulatory Press Release
Read more
Aug 29, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 30 June 2025

Regulatory Press Release
Read more
Aug 25, 2025
2025
Press Release Non-regulatory

Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy

Non-regulatory Press Release
Read more
Aug 25, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee’s Assessment in Cohort 2

Non-regulatory Press Release
Read more
Jun 11, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics postpones final reporting of ELC-100 study due to database transition

Non-regulatory Press Release
Read more
May 28, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company’s oncolytic virus candidates, ELC-100 and ELC-201

Non-regulatory Press Release
Read more
May 27, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics' CEO sells a small portion of his shareholding – remains a long-term major shareholder with strong confidence in the company’s future

Non-regulatory Press Release
Read more
May 22, 2025
2025
Press Release Non-regulatory

Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy

Non-regulatory Press Release
Read more
May 15, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 31 March 2025

Regulatory Press Release
Read more
Apr 10, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee’s assessment of cohort 1

Non-regulatory Press Release
Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.